Lantheus (NASDAQ:LNTH) Stock Rating Lowered by Brookline Capital Markets

Lantheus (NASDAQ:LNTH) was downgraded by equities research analysts at Brookline Capital Markets from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other research analysts also recently issued reports on LNTH. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Truist Financial boosted their target price on Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Mizuho decreased their price target on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $109.71.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $100.00 on Tuesday. The firm has a market cap of $6.51 billion, a PE ratio of 24.10 and a beta of -0.06. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.86. The company has a fifty day moving average price of $103.93 and a 200 day moving average price of $86.41.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the prior year, the company earned $1.53 EPS. The company’s revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the stock. Western Wealth Management LLC bought a new position in Lantheus in the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC increased its position in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter worth approximately $36,000. Finally, Bessemer Group Inc. boosted its holdings in shares of Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.